MEMBRANE PROTEOME ARRAY™
Assess specificity and off-target binding of your biotherapeutic candidates. De-risk your program and choose the right lead molecule.
Membrane Proteome Array: The Leading Solution for Antibody Specificity Profiling

The Membrane Proteome Array is the leading solution for antibody specificity profiling. Our cell-based array contains the largest set of human membrane proteins (including heterocomplexes) assembled to determine specificity and preclinical safety of antibodies, CAR-T cell therapies, and other biotherapeutics.
“MPA technology quickly provided us with the reassurance that Abound Bio’s potent neutralizing antibodies to SARS-CoV-2 did not bind off-target human membrane proteins, which could be associated with toxicity.”
Applications: How you can use the Membrane Proteome Array
“We have been very pleased with the data that we obtained from the Membrane Proteome Array platform. This showed that our antibodies recognize only their select target, and not other membrane proteins in their panel.”
The MPA Advantage: What Makes the MPA so Successful

6,000 membrane proteins (including heterocomplexes)
representing >94% of the membrane proteome



with option for full traceability and auditability

Successfully screened 1000+ molecules
MPA Accepted into FDA’s ISTAND Program
Featured Case Studies
Publications Featuring the Membrane Proteome Array
MPA services are available directly through Integral Molecular or through our distributors







Frequently Asked Questions
The Membrane Proteome Array uses the largest membrane protein library ever assembled, flow cytometry, and unfixed cells for high-sensitivity detection, resulting in the broadest screens and the highest success rates. A typical project involves:
- 1. You send us 500 µg of each antibody that you would like screened
- 2. We optimize conditions for detecting antibody binding in our high-throughput system
- 3. We screen your antibodies on the Membrane Proteome Array under optimized conditions
- 4. We confirm all identified targets in a second flow cytometry titration experiment
- 5. You receive a detailed report containing the membrane protein binding profiles of your antibodies, the identity of validated targets, and publication-quality figures
Our MPA+IND service provides antibody specificity testing and safety profiling information for your IND applications. Through ISTAND, we are working with the FDA toward streamlining your regulatory review process. To learn more, visit MPA Accepted for Consideration under FDA’s ISTAND Program